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A B S T R A C T
Chagas disease has become a global health problem due to migration of infected people out of Latin America to
non-endemic countries. For more than 40 years, only the nitroimidazole compounds Benznidazole and
Nifurtimox, have been used for specific treatment of Trypanosoma cruzi infection with disappointing results,
specially due to the long duration of treatment and adverse events in the chronic phase. In the last years,
ergosterol inhibitors have been also proposed for specific treatment. Different randomized clinical trials were
performed for evaluating their treatment efficacy and safety.
One of the greatest concerns in clinical trials is to provide an early surrogate biomarker of response to try-
panocidal chemotherapy. Serological response is slow and the classical parasitological tests have poor sensitivity
and are time-consuming. Nowadays, PCR is the most helpful tool for assessing treatment response in a short
period of time. Different protocols of PCR have been developed, being quantitative real time PCR based on
amplification of repetitive satellite or minicircle DNA sequences plus an internal amplification standard, the
mostly employed strategies in clinical trials. Standardized protocols and the use of an external quality assessment
ensure adequate technical procedures and reliable data.
Clinical trials have shown a significant reduction in parasite loads, reaching undetectable DNA levels in
bloodstream after specific treatment, however events of treatment failure have also been reported.
Treatment failure could be due to inadequate penetrance of the drugs into the affected tissues, to the presence
of primary or secondary drug resistance of the infecting strains as well as to the existence of dormant parasite
variants reluctant to drug action.
The early diagnosis of drug resistance would improve clinical management of Chagas disease patients, al-
lowing dictating alternative therapies with a combination of existing drugs or new anti-T. cruzi agents.
The aim of this review was to describe the usefulness of detecting T.cruzi DNA by means of real time PCR
assays, as surrogate biomarker in clinical trials for evaluating new drugs for CD or new regimens of available
drugs and the possibility to detect treatment failure.
1. Introduction
Chagas disease (CD), caused by the kinetoplastid flagellate
Trypanosoma cruzi, has been considered as “the most neglected of the
neglected diseases” with research and development gaps related to di-
agnosis and treatment. Although CD has by tradition been treated as an
endemic disease in the tropical and subtropical areas of South America,
it has become a global concern due to migration of infected people to
non-endemic countries. Complex interactions between the parasite and
the mammalian host, as well as eco-epidemiological factors determine
the infection outcome.
The infection passes through an acute and a chronic phase. During
the acute phase, symptoms are variable and mostly decline sponta-
neously after weeks. Appropriate parasitical treatment can eradicate
the parasite. In the chronic phase, approximately 70% of seropositive
individuals are asymptomatic, whereas 30% develop cardiac and/ or
digestive disease manifestations several years or decades later; out of
them, 2–3% present severe forms that can evolve to sudden death. The
factors governing the progression of chronic Chagas disease remain
unknown and no prognostic markers are still available (Pérez-Molina
and Molina, 2018).
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2. Parasitical drugs
For more than 40 years, only two nitro-heterocyclic compounds
have been used for specific treatment of Trypanosoma cruzi infection:
Nifurtimox (NFX) produced firstly by Bayer since 1967 (Lampit®) and
recently also by Gador (Furtimox®) and Benznidazole (BZ) produced by
Roche since 1972, Rochagan® and Radanil®) and discontinued recently,
until LAFEPE and ELEA companies have started their production (Coura
and de Castro, 2002). Although these drugs are far from optimal ac-
tivity, they are effective against infections in the acute phase while their
usefulness in preventing or alleviating symptoms in the chronic stage is
controversial (Urbina, 2010). Numerous clinical trials have reported up
to 80% of parasitological cure in the acute phase (Bahia-Oliveira et al.,
2000) and 60–70% of cure in early chronic phase in children up to 14
years of age (de Andrade et al., 1996; Sosa-Estani et al., 1998, 2009,
Yun et al., 2009; Sales Junior et al., 2017). For this reason, the major
limitation on the use of both drugs is low anti-parasitic activity in the
chronic phase, with only 5–20% of patients considered cured, as as-
sessed after 20 years or more of follow-up (Cancado, 2002; Pinto Días,
2006).
These marked differences in efficacy of the nitroderivatives between
the acute and chronic stages of Chagas disease are unknown (Cancado,
2002). Possible factors involved are probably related to the presence of
different parasite lineages in distinct geographic regions (Carranza
et al., 2009, Zingales et al. 2012, Brenière et al., 2017; Rodrigues-dos-
Santos et al., 2018) with differential drug susceptibility (Filardi and
Brener, 1987; Murta et al., 1998; Toledo et al., 2003; Muñoz-Calderón
et al., 2012) and differences in genetic background, immune response
among human populations (Yun et al., 2009), associated in turn with
the observed geographic differences in therapeutic outcome (Rassi and
Luquetti, 1992; Yun et al., 2009).)
Another factor to be taken into account is the time elapsed between
the onset of infection and drug treatment, because cases (mostly
asymptomatic) treated closer to the acute phase period might display a
more rapid cure. Additionally, with treatment regimens that extend
over several months, failures to complete the therapeutic schedule are
more likely to occur.
3. Early Biomarkers of cure or treatment failure
One of the greatest concerns in clinical trials is to provide an early
surrogate biomarker of response to trypanocidal chemotherapy.
The negativization of two serological tests using crude and re-
combinant antigens is the current criteria of cure in Chagas disease.
However, in the advanced chronic phase, the antibodies decrease is
slow, taking years to complete and requires a long follow-up (Gomes
et al., 2009). In a meta-analysis made by Sguassero et al. in, 2015, the
negativization of conventional serological tests (ELISA, IFI, HIA) was
10% after 48 months of follow-up. In the long-term, the rate of nega-
tivization increased up between 20% and 45% (Sguassero et al., 2015).
On the other hand, negativization of parasitological tests in per-
ipheral blood, hemoculture, xenodiagnosis and/or polymerase chain
reaction (PCR), do not ensure the absence of infection. Indeed, a ne-
gative result cannot be taken as criteria of cure, while a positive result is
a useful marker of treatment failure.
Hemoculture and xenodiagnosis have poor sensitivity, are labor-
ious, time-consuming and only available in reference research institu-
tions with special laboratory biosecurity conditions. In contrast, PCR is
a helpful tool for the early detection of treatment failure and to reduce
the time of follow-up (Britto CC, 2009). Actually, the PCR is the leading
test for assessing responses to treatment in a short period of time
(Pinazo MJ et al., 2015).
4. Polymerase chain reaction based methods for treatment
monitoring
Since its first development, the PCR directed to T.cruzi DNA was
applied to treatment monitoring, but different protocols were described
showing different results of sensitivity, specificity and accuracy after
treatment and during follow-up (Britto C et al., 1995). Many factors
contribute to PCR variability, such as the volume of blood collected,
conditions of sample conservation and transportation, DNA extraction
procedure, molecular targets, sets of primers and probes as well as
thermo-cycling conditions. The best results were obtained using
methods based on the amplification of repetitive satellite DNA
(SatDNA) or minicircle DNA (kDNA) sequences (Schijman et al., 2011).
The implementation of real time quantitative PCR (qPCR) assays
using fluorescent dyes as Sybr Green or TaqMan fluorogenic probes
have shown good results for monitoring treatment response (Schijman
AG, 2018). The qPCR technology adds the possibility of quantifying the
parasite load and the use of an internal control of DNA integrity and/or
PCR inhibition in the same reaction, when using TaqMan probes in
multiplexed reactions. Due to the need of an accurate measurement of
parasitic loads, Ramirez et al. carried out an analytical validation of
qPCR methods targetting the above mentioned sequences, for quanti-
fication of T. cruzi DNA in blood samples (Ramírez JC et al, 2015). Both
targets showed a high concordance in sensitivity and parasitic load
values. Indeed, these validated methods, which use the parasite se-
quences of choice in duplex TaqMan qPCR format coupled to the am-
plification of an internal control, are the ones mostly employed for
treatment monitoring in clinical trials (Moreira OC et al., 2013; Morillo
C et al., 2015; Molina I et al., 2014; Torrico F et al., 2018).
Aiming to enhance the sensitivity of qPCR for monitoring treatment
response in clinical trials, many strategies have been proposed: the use
of a multiplex qPCR using paired kDNA and satDNA, the analysis of
serial blood samples to increase the number of replicates and the ex-
ploration of automatization of DNA extraction procedures (Seiringer P
el al., 2017; Álvarez et al., 2016; Abras A et al., 2018; Parrado R et al.,
2018).
Besides, to ensure the quality of laboratory data, an External Quality
Assurance (EQA) system has been recently designed and implemented
to evaluate the performance of PCR laboratories involved in Chagas
disease diagnosis and treatment monitoring. The system involves the
evaluation of proficiency testing panels containing negative controls
and different dilutions of seronegative human blood spiked with known
quantities of parasite cells obtained by culturing. These specimens are
blindly analyzed and the results evaluated by an external laboratory
(Ramirez JC et al., 2017).
The perspective of the production and validation of commercial kits
for molecular diagnosis and monitoring of T.cruzi infection would im-
prove the performance and reproducibility of home-brewed molecular
tests performed at present by different laboratories in multi center
studies.
The Table 1 shows published clinical trials dedicated to Chagas
disease that employed PCR methodology to detect parasite DNA in
bloodstream as surrogate marker of treatment response.
Nowadays, new trials have been started to evaluate new schemes of
Benznidazole (Multibenz, BENDITA), Nifurtimox (CHICOstudy) and
Fexinidazole with promising preliminary results (unpublished data). All
of them use qPCR for monitoring treatment response and in most of
them, EQA programs have been implemented to enhance the quality of
the laboratory results.
All of these studies have shown a significant reduction in parasite
load to undetectable DNA levels during specific treatment. However, it
has been observed a relapse in parasitic loads after the end of the
treatment with a significant difference between cohorts treated with
Benznidazole and ergosterol inhibitors. The rates of failure of
Benznidazole reached 46% in the BENEFIT study and 39.6% in the
study performed by Galvao et al. after three years of follow-up (Morillo
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et al., 2015; Galvão et al., 2003). However, in Chagasazol and STOP-
Chagas studies, which used posaconazole, the positive results of PCR
increased faster arriving to 90% of positivity during the first year of
follow-up (Molina et al., 2014; Morillo et al., 2017). Among the er-
gosterol inhibitors, only after a regimen of 4000mg/week for 8 weeks
of E1224, a prodrug of ravuconazole, sustained parasitological response
was obtained at 12 months post-treatment period (Torrico et al., 2018).
With respect to clinical follow-up, there was not a significant dif-
ference in PCR results between symptomatic and asymptomatic
chronically infected patients (Molina et al., 2014, Riarte A, unpublished
data). Only in the BENEFIT study, in which all patients included suf-
fered cardiac involvement, it was shown that Benznidazole could re-
duce parasitic loads without significant effect on clinical progression
along 5 years of follow-up (Morillo et al., 2015).
One limitation of the molecular techniques outcomes in clinical
trials of established chronic infections is the short time of follow-up
(1–7 years). It would be necessary to perform such monitoring for
several years to confirm primary results.
Factors exposed above concerning suboptimal efficacy of available
drugs, bring with them the existence of T. cruzi strains refractory to
treatment distributed throughout South America, though the extent to
which this reflects an acquired resistance or natural variation in sen-
sitivity is unknown (Filardi and Brener, 1987; Castro et al., 2006).
5. Treatment failure and drug resistance
Treatment failures have been reported for both drugs used for
treatment of Chagas disease (Britto et al., 1999; de Lana et al., 2009;
Fernandes et al., 2009). However, the difficulties of finding resistant
trypanosomes in the field and the subsequent administration of che-
motherapy make it difficult to attribute these failures to the presence of
drug-resistant parasites and not to the effectiveness of the pharmaco-
logical treatment.
In some organisms (Trichomonas, Giardia and Entameba), re-
sistance to nitroimidazoles is explained by a deficiency in nitro group-
reducing enzymes, but there are no similar studies in T. cruzi. For this
reason, unlike other tripanosomiasis, distinguishing between treatment
failure due to drug resistance or due to other reasons is even more
challenging in the case of Chagas disease. Furthermore, the toxicity of
the available drugs in combination with the need for prolonged treat-
ment regimens has an inevitable impact on patients´ compliance, pro-
viding a selective environment for the development of drug-resistant
parasites.Can primary drug resistance be present in the transmission
cycles?
Up to now, there are no signs for a spread of drug-resistant T. cruzi
strains in the field. However, because of the biological and genetic di-
versity of different populations (Andrade et al., 2004; Zingales et al.,
2012), naturally occurring drug-resistant parasites have been isolated
(Filardi et al., 1987; Murta et al., 1998, 1999). This biological and
genetic diversity could also explain the character of susceptibility of
Tulahuen (DTU VI) and Y (DTU II) strains to NFX and on the other
hand, the resistance of Sonya and Colombiana (DTU I) strain (Neal and
van Bueren, 1988).
Therefore, any point mutation originated could change the general
activity and/or the substrate specificity, inducing drug-resistance
(Murta et al., 2006). Additionally, it should be added that wild popu-
lations of T. cruzi may contain both susceptible and resistant forms to
chemotherapeutic agents so that the destruction of susceptible forms by
drugs leads to the selection and proliferation of resistant subpopula-
tions (Murta and Romanha, 1998).
These resistant forms could enter again the cycle of transmission of
the disease and thus resistant epimastigotes may transmit that property
to the corresponding amastigotes (Nirdé et al., 1995). In this way, drug
resistance can be extended to the infective stage of T. cruzi. (Marra,
1969; Nozaki et al., 1996).
6. Genes associated with generation of drug resistance
The mode of action of nitroheterocyclic compounds appears to in-
volve the metabolic activation of the compounds initiated through the
reduction of the nitro groups mediated by a mitochondrial NADH-de-
pendent type-I nitroreductase (NTR I), which uses FMN as a cofactor
(Hall and Wilkinson, 2012). Another oxidoreductase that uses FMN as a
cofactor and is involved in phenomena of resistance is the Old Yellow
Enzyme (OYE), initially described by Warburg and Christian in, 1932.
These enzymes can reduce nitro esters, nitroaromatics, or α,β-un-
saturated compounds (Yanto et al., 2010) and among its diverse func-
tions they are associated with detoxification, oxidative stress response,
and specific metabolic pathways such as ergot alkaloid biosynthesis
(Toogood et al., 2010).
Equally important is the broad-spectrum of resistance, named
Multidrug Resistance (MDR) phenotype. This MDR phenotype de-
termined by cross-resistance to structurally and functionally unrelated
drugs could be a limiting factor to the treatment of parasitosis. Among
the factors related to the onset of the MDR phenotype, the best char-
acterized is the overexpression of membrane transporters, mostly from
the ATP-Binding Cassette (ABC) protein superfamily (Gottesman,
2002). In this context, the expression of ABC transporters has been
related to chemotherapy failure. The most known ABC transporters are
ABCB1 and ABCC1, involved in the multidrug resistance phenotype in
cancer, given their participation in cellular detoxification. Twenty
seven ABC genes have been identified in the T.cruzi genome. None-
theless, only four ABC genes have been characterized: ABCA3, involved
in vesicular trafficking; ABCG1, overexpressed in strains naturally re-
sistant to Benznidazole, and P-glycoprotein 1 and 2, whose participa-
tion in drug resistance is controversial (Franco et al., 2015; Zingales
et al., 2015).
Other studies have also shown that resistance to NFX can occur
independently of resistance to BZ (Filardi and Brener, 1987). Additional
mechanisms which give rise to resistance against nitroheterocyclic
drugs must exist. Identifying these, using the full complement of post-
genome technologies, must be regarded as a priority in Chagas disease
research.
7. Nitroheterociclic resistance and clinical cohorts of patients
under treatment
There are numerous in vitro studies on the susceptibility of strains of
T. cruzi that have contributed significantly to the knowledge of this
disease. Andrade et al., 1983 and 1992, carried out comparative ana-
lyses of numerous strains of T. cruzi, resulting in two groups of trypa-
nosomes, one susceptible and the other resistant to BZ, which allowed
to establish a correlation with clinical-therapeutic relevance. On the
other hand, Murta et al., 1998, working with a greater number of
strains, obtained a response to chemotherapy in a characteristic way for
each group. Meanwhile, Moreno et al., 2010 developed a methodology
to quantify BZ susceptibility in haemoculture-derived isolates from
patients obtained before and after BZ treatment. Comparison of the in
vitro BZ resistance of the pre-treatment parasites from patients con-
sidered cured and from those experiencing therapeutic failure showed
no correlation with therapeutic outcome.
Most recently, Quebrada Palacio et al., 2018 studying the behavior
of the parasites and performing comprehensive drug sensitivity testing,
demonstrated substantial intra-DTU phenotypic diversity within TcV, a
similar finding to that described by Mejia et al., 2012 for TcI isolates.
In general terms, it can be said that there is still a great knowledge
gap concerning the genetics and biology of infective parasitic popula-
tions in patients under treatment. The early diagnosis of drug resistance
using as source clinical samples would improve the clinical manage-
ment of Chagas disease patients, allowing dictating alternative thera-
pies with a combination of existing drugs or new anti-T. cruzi agents.
However, this is a difficult task, due to the low parasitic load frequently
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observed during the chronic phase of the disease.
8. Final remarks
Currently available diagnostics and trypanomicidal chemotherapy
are suboptimal for adequate control and treatment programs. The de-
sign of novel drugs for Chagas disease is still challenging due to dif-
ferent parasitic-host features, such as the parasite life cycle that in-
cludes intracellular forms which can be in a dormant stage (Sánchez-
Valdéz et al., 2018), its genetic diversity associated with different tissue
tropism (Zingales et al., 2014), the propagation of the infection by
different routes in diverse geographic areas where human ethnicities
display diversity of genetic and immunological backgrounds.
The production of commercial kits to facilitate and improve mon-
itoring of parasite response by means of PCR techniques or novel
strategies such as Loop isothermal amplification or the recombinase
polymerase assay (RPA) for amplification of DNA/RNA-based bio-
markers (Besuschio et al., 2017; Jimenez-Coello et al., 2018), the search
for improved nucleic acid extraction protocols adapted to different
types and volumes of clinical samples, the validation of different sta-
bilizing agents to allow adequate sample conservation especially in
rural endemic areas, the development of technical procedures allowing
evaluation of parasite persistence in target tissues even after etiological
treatment, such as sensitive detection of amastigote forms using Re-
verse transcription polymerase chain reaction (RT-PCR) of amastigote-
specific genes are some challenges to face in the future in order to
validate the detection of parasite nucleic acids as surrogate markers of
treatment outcome.
Such tasks require a strong coordinated action between interna-
tional non-profit Organizations, Foundations, Pharmaceutical
Companies and Academia to promote sufficient investments devoted to
develop and evaluate better solutions for treating this neglected disease
(Reithinger et al., 2009).
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